


Anti-microbial susceptibility testing (AST) and bacteria detection assisting patients and antibiotics.



- Antibiotic resistance is a factor in Gonorrhea and Sepsis infections. Each year there are 1.6M and 1.7M cases of each respectively ^{1,2}.
- Phenotypic AST yields precise targeted treatments, but current methods take days, leading to late results and limited use.
- Acenxion's prototype provides **phenotypic AST results in 4-6 hours** allowing fast, targeted treatments to heal patients.
- Targeted treatments also extend the service life of antibiotics by quickly eliminating microbes and mitigating AMR risk.



- AST is a \$3B global market with a 6% CAGR. Consumables are 73% of those expenditures.
- Detection is a \$4B global market with a similar rate for consumables.
- By 2027, detection and AST are projected to be a combined \$13B annual global market.
- By contrast, only 13 new antibiotics are in Phase 3 trials.³ Health experts insist we increase AST to enhance antibiotic stewardship.⁴
- Acenxion's core development team previously developed and marketed numerous devices. We have the skills and network to succeed.
- Acenxion's prototype is scalable and seamlessly integrate into current laboratory workflows.
- Acenxion seeks participants in post-money SAFE Agreements to complement a multi-million dollar NIH grant.

A diagnostic partner for patients and antibiotics

1. 2021 CDC report, "Sexually Transmitted Infections Prevalence, Incidence, and Cost Estimates in the United States"
2. 2018 Clinical Infectious Diseases, "Combating Sepsis: A Public Health Perspective",
3. 2020 Pew Charitable Trust report, "Tracking the Global Pipeline of Antibiotics in Development, April 2020"
4. 2019 CDC report, "Antibiotic Resistance Threats in the United States."

Acenxion Biosystems Company Profile

Contact
Dr. Roy Swiger, CEO
roy@acxbio.com
321-749-0523

2002 West 39th Ave, Suite 1004 · Kansas City · KS · 66103-2943 www.acenxionbiosystems.com